Full history for every metric is available with a Kvantra account
Pardes Biosciences, Inc. (PRDS)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | - | 0 | 0 | 0 |
| Operating profit | $m | -100 | -85 | |||||
| Net profit | $m | - | - | - | - | -39 | -93 | -71 |
| EPS reported | $ | -1.61 | -1.20 | |||||
| Operating cashflow per share | $ | -1.24 | -1.24 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.24 | -1.24 | |||||
| Free cash flow | $m | -72 | -79 | |||||
| Net debt | $m | -197 | -153 | |||||
| Book value equity | $m | 180 | 155 | |||||
| Book value per share | $ | 3.10 | 2.58 | |||||
| Number of shares | m | 58.13 | 60.21 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.55 | 0.87 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -1.36 | -1.72 | |||||
| EV/EBITDA LTM | x | -0.42 | 0.23 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -95.13% | -73.75% | |||||
| FCF Yield | % | -73.27% | -58.24% | |||||
| Quality | ||||||||
| ROE | % | -51.86% | -41.86% | |||||
| ROIC | % | -53.57% | -53.57% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.63 | 0.63 | |||||
| EBIT/Net interest | x | -31.36 | -31.36 | |||||
| Net debt/market cap | % | -200.89% | -113.32% | |||||
| Net debt/Equity | x | -1.10 | -0.99 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, developing, and marketing groundbreaking treatments. The company's core objective is to improve outcomes for patients battling life-threatening illnesses. Its primary investigational therapy, PBI-0451, is currently progressing through clinical development with the aim of both treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and their related health issues. Established in 2020, Pardes Biosciences maintains its corporate headquarters in Carlsbad, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Pardes Biosciences, Inc. (PRDS)
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, developing, and marketing groundbreaking treatments. The company's core objective is to improve outcomes for patients battling life-threatening illnesses. Its primary investigational therapy, PBI-0451, is currently progressing through clinical development with the aim of both treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and their related health issues. Established in 2020, Pardes Biosciences maintains its corporate headquarters in Carlsbad, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free